Further details of the agreement were not disclosed, including details on revised drug prices or which medicines are covered.
More on Johnson & Johnson
- Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
- Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting
- Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
- J&J submits application for FDA approval of OTTAVA robotic surgical system
- J&J succeeds in mid-stage trial for SLE therapy